HOWL Werewolf Therapeutics
- 4.850
- -0.080-1.62%
- 4.830
- -0.020-0.41%
Werewolf Therapeutics News
Werewolf Therapeutics: Buy Rating Affirmed Amid Promising Clinical Advancements and Pipeline Potential
Werewolf Therapeutics Price Target Maintained With a $12.00/Share by JMP Securities
Werewolf Therapeutics Price Target Maintained With a $12.00/Share by JMP Securities
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
Werewolf Therapeutics (NASDAQ:HOWL) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table provides a quick ove
J.P. Morgan Securities: Reiterated the Werewolf Therapeutics (HOWL.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.
J.P. Morgan Securities: Reiterated the Werewolf Therapeutics (HOWL.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics with a Buy and maintains $15 price target.
Buy Rating Affirmed for Werewolf Therapeutics Amid Promising Financials and Anticipated Clinical Updates
Werewolf Therapeutics (HOWL.US): The 2024 Q1 financial report achieved revenue of US$742,000, with a previous value of US$4.464 million and an expected value of US$1.82 million; earnings per share were -0.39 dollars, previous value was -0.34 dollars, and
Werewolf Therapeutics (HOWL.US): The 2024 Q1 financial report achieved revenue of US$742,000, with a previous value of US$4.464 million and an expected value of US$1.82 million; earnings per share were -0.39 dollars, previous value was -0.34 dollars, and expected value was -0.35 dollars.
Werewolf Therapeutics Q1 EPS $(0.39) Misses $(0.35) Estimate, Sales $742.00 Miss $1.82M Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.35) by 11.43 percent. This is a 14.71 percent decrease over losses
Werewolf Therapeutics 1Q Loss/Shr 39c >HOWL
Werewolf Therapeutics 1Q Loss/Shr 39c >HOWL
Press Release: Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update -- Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124
Press Release: Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Company to present an update of its ongoing
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
First Data Demonstrating Application of PREDATOR Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (
Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
Institutional Owners May Ignore Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Recent US$53m Market Cap Decline as Longer-term Profits Stay in the Green
Key Insights Institutions' substantial holdings in Werewolf Therapeutics implies that they have significant influence over the company's share price 50% of the business is held by the top 6 sharehol
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
Werewolf Therapeutics (Nasdaq: HOWL) is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
JMP Securities Initiates Coverage On Werewolf Therapeutics With Market Outperform Rating, Announces Price Target of $12
JMP Securities analyst Reni Benjamin initiates coverage on Werewolf Therapeutics with a Market Outperform rating and announces Price Target of $12.
Werewolf Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/03/2024 88.09% JMP Securities → $12 Initiates Coverage On → Market Outperform 03/07/2024 135.11% HC Wai
Buy Rating for Werewolf Therapeutics: Innovation and Financial Stability Signal Promising Future in Immunotherapy
Analysis
Price Target
No Data
